BTOG wishes to inform members of a new NICE approval that has been published today.
NICE has appraised selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer and BTOG is delighted it has been given a positive recommendation for the following:
Selpercatinib is recommended with managed access as an option for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) in adults, only if:
• it is untreated
• the conditions in the managed access agreement for selpercatinib are followed.
BTOG notes that RET-testing by RNA fusion panel is already on the NHS Test Directory. Please make sure your testing processes are optimised to allow equity of access to 1st line patients.
For further details and the documents, please see the NICE website.